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Abstract: Selective inhibitors of tyrosine kinase 2 (Tyk2) were searched for using database screening, de novo
ligand design and computational docking in Tyk2 and seven other protein kinases. None of the structures in
the National Cancer Institute database seem to inhibit Tyk2 selectively, but five of the designed structures
seem promising.
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INTRODUCTION transfer of the γ  phosphate of adenosine triphosphate (ATP)
to the hydroxyl group of a tyrosine residue in the STAT
protein. After phosphorylation on tyrosine residues, the
STAT molecules form homo- or heterodimers [9], which are
translocated into the nucleus. The STAT proteins then bind
to DNA, and activate gene transcription [2]. The Jak-STAT
signalling cascade has been shown to contribute to growth
and survival of e.g. human multiple myeloma cells [13],
acute lymphoblastic leukaemia [14] and a variety of other
malignancies [15, 16]. This makes the Janus kinases
potential targets for new cancer therapies. One way to
interrupt this signalling cascade is to block the binding of
ATP to the tyrosine kinases. ATP analogues are generally
non-selective, but the development of inhibitors like STI571
[17] shows that ATP binding sites can be used as targets for
selective drugs.
Protein kinases contribute to regulation and coordination
of e.g. metabolism, gene expression, cell growth, cell
motility, cell differentiation and cell division [1]. The Janus
kinase (Jak) family of non-receptor tyrosine kinases consists
of four known mammalian proteins (Tyk2, Jak1, Jak2 and
Jak3) that play a critical role in initiating signalling cascades
of a large number of cytokine receptors [2-5]. All Jak family
kinases possess a carboxyl-terminal tyrosine kinase catalytic
domain, a central kinase-like domain, and a large amino-
terminal region, which has been subdivided into five Jak
homology regions (JH7 to JH3) based on sequence
conservation [5, 6]. In contrast to most other cytoplasmic
protein tyrosine kinases, the Janus kinases have no Src
homology (SH2 or SH3) domains [2]. The specific and non-
covalent association of these kinases to the intracellular
region of cytokine receptors governs their activation upon
ligand binding [3]. The JH domains have been shown to be
the parts of the Janus kinases that are associated with the
cytoplasmic domains of cytokine receptors [3, 5, 7]. The
activation of the Janus kinases is mediated by ligand-
induced receptor oligomerisation [8-10]. The Janus kinases
are activated by e.g. the type I interferons (IFNα/β and γ ),
the interleukins (IL2-7, IL-10 and IL-12), growth hormone
(GH), prolactin, erythropoietin (Epo), granulocyte-specific
colony-stimulating factor (G-CSF), granulocyte-macrophage
colony-stimulating factor (GM-CSF), leukaemia inhibitory
factor (LIF) and ciliary neurotrophic factor (CNTF) [2, 5,
11].
At the present time none of the Janus kinases has
experimentally determined 3-dimensional (3D) structures
[18, 19]. In a recent publication, we predicted the 3D
structures of the tyrosine kinase domains of Jak2 and Tyk2
by homology modelling, and suggested functional groups
for a selective inhibitor of Tyk2 based on Protein Alpha
Shape Similarity Analysis (PASSA) [20]. PASSA is a new
method for mapping protein binding sites, and is especially
suited for protein structures predicted by homology
modelling. In PASSA, several models for the same protein
are used together with structures of other, related proteins to
single out unique features of the target protein. Hence, this
method is developed especially for design of selective drugs.
In PASSA, the binding sites of the protein structures are
compared using gaussian property distributions. The results
are combined with results from Multiple Copy
Simultaneous Search (MCSS) [21], to suggest functional
groups of a selective inhibitor. The use of gaussian functions
to describe the protein binding sites makes PASSA
especially suited for use with homology modelled structures,
since the functional form of the representation may be more
robust than force field based methods against small
structural errors typically present in homology models.
Homology modelling in drug design has recently been
reviewed [22].
Activated Janus kinases autophosphorylate [3] and
phosphorylate the cytokine receptors with which they are
associated, providing binding sites for the Signal
Transducers and Activators of Transcription (STAT) family
of transcription factors [8]. The Jaks catalyse
phosphorylation of the STAT proteins (seven isoforms,
STAT1-4, STAT5A-B and STAT6) [12], which occurs by
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This work utilised previously suggested functional
groups for a selective Tyk2 inhibitor [20] in a
pharmacophore search of the database of the National Cancer
Institute (NCI). The resulting structures were tested for
binding to Tyk2 by computational docking in a homology
model of Tyk2. Structures having the desired functional
groups were also generated by de novo ligand design. The
most promising drug candidates resulting from this analysis
were tested for selectivity towards Tyk2 by computational
docking in seven protein kinase structures, in addition to the
homology model of Tyk2.
geometries of small molecules quite well [28]. A smooth
non-bonded cut-off of 10-12 Å was used. In the PAS-Dock
docking method, a score function based on gaussian property
descriptions was used. Both methods use Tabu search [25]
for the geometry search.
Docking with MOE-Dock
ATP has previously been docked into the homology
model of Tyk2 [20]. The hits from the pharmacophore search
having atoms within 10 Å of the docked conformation of
ATP were docked into the homology model of Tyk2 as a
first screening, using ten MOE-Dock runs of 1000 iterations
each. A docking box of 125x125x125 grid points with
0.375 Å spacing between each grid point was used. The
docking box was centred on the docked conformation of
ATP. All structures from this docking analysis having
docking energies <5000 kcal/mol (112 structures) were
further docked using ten runs of 25000 iterations each. This
threshold of 5000 kcal/mol was chosen based on the
distribution of the docking energies.
METHODS
Pharmacophore Search
The 3D structure database of the NCI from August 2000
(http://cactus.nci.nih.gov/) (250 241 structures) was searched
using the pharmacophore search routines in Molecular
Operating Environment (MOE) [23, 24]. Functional groups
for a selective Tyk2 inhibitor have been proposed earlier by
our group [20], based on MCSS. Selected MCSS fragments
[20] defined the pharmacophore, that is, the ligand functional
groups that are proposed for a selective Tyk2 inhibitor (Fig.
(1)). MOE uses “pharmacophore query features” to represent
the pharmacophore. A query feature is a point in space with
a radius-like tolerance on spatial proximity and an associated
expression indicating electrostatic properties. These query
features represent volumes in space where ligand functional
groups with specified properties (e.g. aromatic) should be
found. The MOE pharmacophore search routines search for
matches between the functional groups of the ligands in a
database and the pharmacophore query features. The query
features used correspond to the MCSS fragments found in
the previous study [20]. To allow some variation from the
MCSS fragments, the following proximity tolerances were
used for the different query features: Aromatic (benzene
rings): 4.0 Å, hydrophobic (CH3-groups): 2.0 Å, hydrogen
donor or hydrogen acceptor: 1.6 Å. Proximity tolerances of
about twice the actual size of the fragments were used as a
compensation for potential inaccuracies in the computational
methods used. This is important in order to limit the
number of false negatives. A match on at least six of the
pharmacophore query features (MCSS fragments) was
required in the pharmacophore search. The resulting
compounds were first filtered according to distance from the
ATP binding site. All compounds having atoms within 10
Å of the docked conformation of ATP [20] were kept for
further analysis.
MOE-Dock uses grid-based potential fields [23] to
calculate interaction energies between the ligand and the
receptor. This grid-based method calculates the potential
energy grids only once, at the beginning of the docking
procedure. Hence, protein flexibility is not taken into
account in these calculations.
The conformation of each drug candidate having the
lowest docking energy was also scored using the gaussian-
based score function used in the new docking method PAS-
Dock [26].
Docking with PAS-Dock
The structures from the pharmacophore search of the NCI
database described above were also docked using the newly
developed docking method PAS-Dock [26]. The largest and
most flexible compounds (917 out of 1168 structures) were
removed from the compound set prior to the docking. The
1168 compounds were sorted according to the Kier
flexibility index [29], and a threshold value for the Kier
flexibility index was chosen by inspection of the structures.
Structures containing several long, un-branched hydrocarbon
chains or large ring systems and structures larger in diameter
than the ATP-binding pocket of Tyk2 were considered
unlikely to fit into the binding pocket.
A docking analysis with 100 Tabu runs of 1000
iterations each was carried out using a docking box with 3 Å
padding around the protein structure. MMFF94 with a
smooth non-bonded cut-off of 10-12 Å was used. A
threshold value of 500 kcal/mol for the ligand Lennard-Jones
potential was used in the geometry search [26]. This docking
method is independent of hydrogen atoms and partial
charges.
Computational Docking Analysis
The hits from the pharmacophore search were docked in a
previously reported [20] homology model of Tyk2. Two
different docking procedures were used: Docking with MOE-
Dock [23, 25], and docking with Protein Alpha Shape
(PAS) Dock, a new docking method recently developed by
our group [26]. MOE-Dock uses the sum of the electrostatic
and the dispersive interaction energy between the ligand and
the target and the intramolecular energy of the ligand to rank
the structures. The molecular mechanics (MM) force field
MMFF94 [27] was chosen for the docking study, as it
predicts both intermolecular hydrogen bonding and
De Novo Ligand Design
LigBuilder [30] was used to design new structures
having the required functional groups. Structures were built
using selected molecular fragments from previous MCSS
results [20] as “seed” structures in the “GROW” function of
LigBuilder. The binding pocket of Tyk2 was defined by the
MCSS fragments defining the Tyk2 pharmacophore. The
resulting structures were energy minimised in MOE [23]
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(100 iterations with steepest descent, 100 iterations with
conjugate gradient and 200 iterations with truncated Newton
optimisation) in complex with the homology model of Tyk2
with all receptor atoms fixed. The force field MMFF94 [27]
with implicit solvation was used. Following the energy
minimisation, the structures were ranked according to
binding affinities estimated using the PAS-Dock scoring
[26].
binding affinity estimated using the PAS-Dock score
function for all compounds in Table 1, except for the
compound with NSC number 27773. The correlation
coefficient is 0.97 when the data for compound 27773 is
kept out of the calculation. Compound 27773 is very
hydrophobic compared to the other compounds in Table 1.
The PAS-Dock score function has been shown to predict
hydrophobic interactions better than hydrophilic interactions
[26]. This might explain the difference between the results
obtained with MOE-Dock and PAS-Dock for this
compound.
The most promising structures from the de novo ligand
design were tested for similarity to the compounds in the
NCI database using the pharmacophore search routines in
MOE [23, 24]. To approximate the size of the functional
groups of the ligands, the following proximity tolerances
were used for the different pharmacophore query features:
Aromatic rings: 2.0 Å, hydrophobic groups: 1.8 Å,
hydrogen donor or hydrogen acceptor: 0.8 Å.
Table 1. Results from Computational Docking of Selected
Structures from the NCI Database with MOE-Dock
NSC number Docking energy from
MOE-Dock (kJ/mol)
Estimated binding
affinitya to Tyk2 (kJ/mol)




3766 -37.1 -0.01To test the most promising drug candidates from the
pharmacophore search and the de novo ligand design for
selectivity towards Tyk2, they were docked in the following
kinase structures, in addition to the homology models of
Tyk2 and Jak2 [20]: RCSB Protein Data Bank (PDB) [18,
19] entries 1ir3 (Insulin-receptor tyrosine kinase in complex
with a peptide substrate and an ATP analogue), 1byg (C-
terminal Src kinase in complex with an inhibitor), 1fgk
(tyrosine kinase domain of Fibroblast growth factor receptor
1), 1fpu (Abelson (Abl) kinase in complex with an
inhibitor), 1qcf (Haematopoetic cell kinase (Hck) bound to
an inhibitor) and 1qpc (Lymphocyte-specific kinase (Lck) in
complex with an inhibitor). The ligand structures were
removed from the X-ray structures and the protein structures
were aligned to the homology model of Tyk2 in MOE prior
to docking. A modified version of the Needleman and
Wunsch approach [31] with a structural correction and the
Blosum 62 [32] similarity matrix was used for the sequence
alignments. The 3D structures were superposed as described
by Shapiro et al. [33]. The docking analysis was performed
with PAS-Dock as described above.
29377 -3.31 -0.03
27773 26.3 -4.59
a The binding affinity was predicted using the PAS-Dock score function [26].
Comparison of the placement of these ligands in the
Tyk2 binding site with the Tyk2 pharmacophore showed
that none of the docked conformations of the ligand
structures had functional groups completely overlapping
with the pharmacophore. The ligand structure with NSC
number 40148 is also small, and very flexible. The docked
structure of this ligand had groups overlapping with the
oxygen-containing sugar ring in the docked conformation of
ATP. It is therefore not likely to be Tyk2 selective. The
hydrophobic rings of ligand structure 159203 were placed
close to benzene rings “5” and “6” from Fig. (1), but the
ring structures were not overlapping. This may, however, be
caused by inaccuracies in the docking analysis. This
structure is therefore considered to be a possible drug
candidate, in spite of the low estimated binding affinity. The
same is true for the ligand structures with NSC numbers
3766 and 29377. The hydrophobic part of ligand structure
27773 was overlapping with benzene ring “5”, but in the
same way as 40148, this ligand is small and flexible, and
therefore not likely to be selective to Tyk2.
RESULTS AND DISCUSSION
Pharmacophore Search and Docking
The Tyk2 pharmacophore used for searching the NCI
database (and for de novo ligand design) was based on
previously selected molecular fragments from MCSS [20].
These fragments are shown together with the docked
conformation of ATP [20] in Fig. (1). Pharmacophore
searching of the NCI database resulted in 1168 compounds
having properties that matched at least six of the specified
functionalities, and were placed within 10 Å of the docked
conformation of ATP.
The mean experimental binding affinity for the set of
structures used to train PAS-Dock [26] was -35 kJ/mol.
None of the docked structures from MOE-Dock had
estimated binding affinities below -35 kJ/mol. This
indicates that even though some of the structures in the NCI
database have functional groups that match the Tyk2
pharmacophore, they may not bind very strongly to Tyk2.
For comparison, the binding affinity was also estimated
in the same way for six different X-ray structures of protein
kinases in complex with known ligands from the PDB [18,
19]. Some of these X-ray structures were used as templates
in the homology modelling of Tyk2 [20]. The average
estimated binding affinity for these six protein kinase
complexes was -18 kJ/mol (Table 2). None of the
compounds from the NCI database shown in Table 1 had
estimated binding affinities below -18 kJ/mol. However,
Docking with MOE-Dock
The five compounds from the NCI database that were
predicted to have the lowest docking energy by MOE-Dock
are listed in Table 1. The docking energies are shown
together with the estimated binding affinity to Tyk2
predicted using PAS-Dock scoring. There is good correlation
between the docking energies from MOE-Dock and the
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when the 112 docked structures from the last MOE-Dock
screening were sorted according to binding affinities to Tyk2
estimated using the PAS-Dock score function (keeping the
ligand conformations produced by MOE-Dock), three of the
compounds had binding affinities below -18 kJ/mol (Table
3). The docked conformations of 116725 and 167941 were
both placed close to benzene rings “5” and “6”, while the
docked conformation of 231503 was placed close to
fragments “1”-“4” from Fig. (1).
for the set of X-ray structures used to train PAS-Dock, new
structures were generated with de novo ligand design, in
order to find compounds that bind more strongly to Tyk2.
De Novo Ligand Design
In each LigBuilder run, 200 candidate structures were
generated. Benzene rings “1”, “5” and “6” (Fig. (1)) were
used separately as “seed” fragments. Two LigBuilder runs
with benzene rings “5” and “6”, respectively, and one
LigBuilder run with benzene ring “1” were carried out. In
total, 1000 structures were generated. Estimation of binding
affinities for these structures using the PAS-Dock score
function [26] showed that using benzene ring “1” from Fig.
(1) as “seed” fragment resulted in the most promising drug
candidates. In total, 162 of the de novo compounds had
predicted binding affinities below the mean experimental
binding affinity for the set of structures used to train PAS-
Dock [26] (-35 kJ/mol). One of these compounds was
generated with benzene ring “5” as “seed” fragment (called
“5_1”), while all the other compounds were generated with
benzene ring “1” as “seed” fragment (“1_1”-“1_161”). Table
5 shows the estimated binding affinities for the structures
generated using benzene ring “1” with estimated affinity
below -45 kJ/mol (ten structures), together with the one
compound generated with benzene ring “5” as “seed”
fragment having estimated affinity below -35 kJ/mol. The
most promising structures from Table 5 according to Tyk2
selectivity (see Table 6) are shown in Fig. (5).
Table 2. Estimated Binding Affinities for Protein Kinases in
Complex with Known Ligands (from Experimental
Structures)







a The binding affinity was predicted using the PAS-Dock score function [26].
Table 3. The Three Compounds from the NCI Database
Having Estimated Binding Affinities to Tyk2
Below -18 kJ/mol
Table 5. Estimated Binding Affinities to Tyk2 for the Most












a The binding affinity was predicted using the PAS-Dock score function
[26]. 1_3 -46.89
Docking with PAS-Dock 1_4 -46.88
In the same way as for MOE-Dock, docking with PAS-
Dock [26] did not identify any compounds from the NCI
database with estimated binding affinities to Tyk2 below -35
kJ/mol. However, one of the structures had estimated
binding affinity below the average for the six X-ray
structures of protein kinase complexes in Table 2 (-18
kJ/mol). The estimated binding affinity to Tyk2 for this
compound is given in Table 4. The docked conformations of
this compound from docking with MOE-Dock and PAS-







5_1 -35.99Table 4. Results from Computational Docking of Selected
Structures from the NCI Database with PAS-Dock
[26]
a The binding affinity was predicted using the PAS-Dock score function [26].
The results in Table 5 show that the estimated binding
affinities for the structures generated with LigBuilder are
much stronger than for any of the compounds from the NCI
database. Hence, these structures are more likely to be
effective as Tyk2 inhibitors. There is, however, no guarantee
that they do not bind to other kinases as well. The
selectivity of these compounds towards Tyk2 was tested by
computational docking.
NSC number Estimated binding affinity to Tyk2 (kJ/mol)
116725 -26.13
Since none of the two docking methods used in this
work were able to identify any compounds from the NCI
database with estimated binding affinities below the average
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Table 6. Estimated Binding Affinities (kJ/mol) for the Most Promising Drug Candidates After Docking in Seven Protein Kinase
Structures in Addition to the Homology Model of Tyk2
Ligand structure Estimated binding affinity (kJ/mol)
Tyk2 Jak2 1ir3 1byg 1fgk 1fpu 1qcf 1qpc
159203 - - - - - - - -
3766 - - - - - - - -
29377 - - - - - - - -
116725 -26.13 - -33.06 - - - - -
167941 - - - - - - - -
231503 -1.73 - -1.31 -1.30 - - - -1.85
“1_1” -4.35 -6.50 -5.80 -3.91 -6.19 -1.98 -7.98 -4.79
“1_2” -49.56 - -6.61 - - - -6.86 -
“1_3” -4.46 -6.04 -5.56 -3.81 -5.66 -5.47 -7.93 -
“1_4” -0.013 - - - - - - -3.60
“1_5” -5.91 -6.66 -5.59 -3.86 -4.63 -5.24 -7.14 -5.06
“1_6” - - -4.41 - - -1.86 -0.93 -
“1_7” -46.14 -6.27 -5.31 -4.14 -5.87 -5.79 - -5.66
“1_8” -22.66 - -7.22 - -4.00 - - -
“1_9” -42.56 -5.74 -5.22 -3.76 -4.69 -5.24 -7.08 -4.97
“1_10” -43.26 -6.89 -5.34 -4.20 -5.0 -0.90 -8.16 -5.47
“5_1” -4.01 - -0.0002 - -0.021 - -6.89 -
Testing of Promising Drug Candidates for Selectivity to
Tyk2
shows the docked conformation of this compound in insulin
receptor tyrosine kinase, together with the ligand in PDB
entry 1ir3. As Fig. (3 B) and (4) indicate, binding of this
ligand does not seem to be ATP competitive. The fragments
shown in Fig. (1) were chosen based on Tyk2 selectivity.
Since ATP binds to all protein kinases, choosing a binding
site other than the ATP binding site might increase
specificity. However, only experimental studies can verify
whether binding of these compounds inhibits Tyk2 activity.
The six most promising structures from the docking
analysis with MOE-Dock and the gaussian-based method
PAS-Dock (159203, 3766, 29377, 116725, 167941 and
231503), together with the eleven structures in Table 5 were
docked in seven protein kinase structures, in addition to
Tyk2, using PAS-Dock. The estimated binding affinities are
shown in Table 6. The docking method PAS-Dock was
chosen for this study, since it was developed especially for
use with homology modelled proteins [26]. The use of
gaussian functions gives a representation that may be more
robust than force field based methods against small
structural errors typically present in homology models.
Homology models of Tyk2 and Jak2 were used here.
Fig. (3 B) and Fig. (4) show that the orientation of
116725 is different in insulin receptor tyrosine kinase
compared to Tyk2, but this compound utilises the same
pocket in both structures. Hence, this pocket may not be the
best choice in the design of a selective Tyk2 inhibitor.
Compounds that bind in the same pocket as fragments “1”-
“4” may be more promising. The much stronger estimated
binding affinity for the structures generated with LigBuilder
using benzene ring “1” as “seed” fragment (Table 5), and the
fact that compound “5_1” is not Tyk2 selective according to
the results in Table 6, support this assumption. Compound
231503 binds in this pocket according to the MOE-Dock
study, but the results from docking with PAS-Dock
indicated the contrary. According to the results presented in
Table 6, this compound is not Tyk2 selective. None of the
other compounds from the NCI database binds in this
pocket. Hence, the structures generated with LigBuilder may
be more promising as drug candidates. The results from our
docking analysis (Table 6) indicate that five of the structures
generated with LigBuilder are selective inhibitors of Tyk2
(Fig. (5)).
The entries in Table 6 for which no results are reported
indicate ligand placements outside the grid used to estimate
the binding affinity. Hence, these ligands are docked outside
the binding pocket of the proteins. Ligands binding outside
the active site region are less likely to inhibit activity, and
therefore not included in this study.
The results in Table 6 indicate that the compound with
NSC number 116725 might be a selective inhibitor of Tyk2
and insulin receptor tyrosine kinase. As shown in Fig. (3
A), the docked structure of 116725 overlaps with benzene
rings “5” and “6” from the Tyk2 pharmacophore shown in
Fig. (1). Hence, this compound may be a promising drug
candidate. The docked conformation of 116725 in the
homology model of Tyk2 is shown in Fig. (3 B). Fig. (4)
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Fig. (1). The Tyk2 pharmacophore used for the database
search and de novo ligand design. The pharmacophore was
defined by fragments from MCSS [20]. The MCSS fragments
are numbered from 1 to 12. The docked conformation of ATP
[20] is also shown.
Fig. (2). The docked conformations of 116725 produced by
MOE-Dock (green) and PAS-Dock (blue).
Fig. (3). A: The docked conformation of 116725 in the homology model of Tyk2, together with benzene rings “5” and “6” from the
Tyk2 pharmacophore (rotated compared to Fig. (1)). The ligand is rendered in “ball and stick”, while the fragments are rendered in
“stick”.
B: The docked conformation of 116725 in the homology model of Tyk2 (rotated compared to Fig. (1)), together with the docked
conformation of ATP [20]. The docked conformation of ATP is included only for visualisation, and was not included in the docking
calculations for compound 116725.
Fig. (4). The docked conformation of 116725 in insulin receptor tyrosine kinase, together with the X-ray structure of insulin receptor
tyrosine kinase in complex with ANP-Mg (PDB entry 1ir3). The structure of ANP-Mg is included only for visualisation, and was not
included in the docking calculations for compound 116725.






















































Fig. (5). The structures of the compounds generated by de novo ligand design that are Tyk2-selective according to our results (“1_2”
(1), “1_7” (2), “1_8” (3), “1_9” (4) and “1_10” (5), respectively). The fragments from the Tyk2 pharmacophore are indicated by the
encircled numbers.
The primary template used in the homology modelling
of Tyk2 [20] was the X-ray structure in PDB entry 1qpc
(Lck in complex with an inhibitor). A common problem
with homology modelling is that the model is more similar
to the primary template than to the target protein [34]. The
results in Table 6 indicate that this is not the case for the
homology model of Tyk2 used here, since there is no strong
correlation between the estimated binding affinities for 1qpc
and Tyk2. If these protein structures were very similar, one
would expect the same compounds to bind to both proteins.
way as the compounds in Table 6, these compounds were
docked in the homology model of Tyk2 and seven other
protein kinase structures. The results are given in Table 7.
As the results in Table 7 indicate, none of the
compounds in the NCI database found to resemble the most
promising structures from the de novo ligand design show
selectivity towards Tyk2. They all have relatively low Tyk2
activity. Compound 624404 potentially binds to Jak2 and
Abl kinase (PDB entry 1fpu). The binding to Jak2 might be
an artefact, as the X-ray structure in PDB entry 1fpu (Abl
kinase bound to an inhibitor) was the primary template used
for the homology modelling of Jak2 [20].
The compounds in the NCI database were searched for
similarity to compound (1)-(5), the most promising
structures from the de novo ligand design. A match on the
pharmacophoric properties of these structures was found for
the fourteen structures in Table 7. These compounds were
missed in the original pharmacophore search. In the same
CONCLUSION
The NCI database has been screened for compounds with
potential for selective binding to Tyk2, using two different
514    Letters in Drug Design & Discovery, 2005, Vol. 2, No. 7 Tøndel and Drabløs
Table 7. Estimated Binding Affinities (kJ/mol) from Docking of the Compounds in the NCI Database Resembling the Most
Promising Structures from De Novo Ligand Design
Estimated binding affinity (kJ/mol)
NSC number Resembling structure Tyk2 Jak2 1ir3 1byg 1fgk 1fpu 1qcf 1qpc
340033 “1_2” -2.22 - -3.84 -1.81 - -4.05 -6.45 -3.53
372408 “1_2” -4.01 -5.31 -3.72 -2.53 -4.16 -4.17 - -3.69
372452 “1_2” -3.71 -5.28 - -2.34 -1.02 -4.27 -7.21 -3.66
623329 “1_2” -3.50 -6.61 -6.71 -2.36 -5.71 -5.95 -8.78 -5.39
624404 “1_2” -3.96 -18.49 -5.95 -9.17 -3.84 -15.77 -5.16 -8.84
627686 “1_2” - - - - - - - -
629605 “1_7” - -5.69 -5.54 -3.56 -2.72 - -8.94 -4.90
25585 “1_8” -2.68 - -0.27 - - -2.67 - -2.79
119957 “1_8” -0.32 - - - - -8.79 - -
138557 “1_8” - - - - - - - -
142574 “1_8” - - - - - - - -
157622 “1_8” - - -0.66 - - - - -
203969 “1_8” - - - - - - - -
633715 “1_9” - - - - - - - -
docking methods. The results from the docking analysis
indicated that none of the structures present in the NCI
database can be used to inhibit Tyk2 selectively. Even
though the two docking methods did not give the same
ranking of the drug candidates, they both produced the same
conclusion, namely that there are no promising Tyk2
inhibitors in the NCI database. The main purpose of docking
methods is to identify the most active compounds. Most
docking methods (as these two) are also trained using X-ray
structures of protein-ligand complexes. Hence, internal
ranking of inactive compounds is bound to fail, and not
interesting for drug design purposes. This may be the reason
why the two docking methods ranked the compounds in the
NCI database differently. However, this analysis provides
useful information about parts of the structures that may be
used as functional groups of a selective inhibitor of Tyk2,
and one compound was found to be a potential selective
inhibitor of Tyk2 and insulin receptor tyrosine kinase.
Several promising structures were proposed by de novo
ligand design. These were tested for selectivity towards
Tyk2 by computational docking in seven protein kinase
structures, in addition to Tyk2. This study indicated that
five of the generated structures might be potential selective
inhibitors of Tyk2.
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